Givlaari (givosiran): Liver Disease Treatment Side Effects & Warnings


Generic drug: givosiran

Brand name: Givlaari

What is Givlaari (givosiran), and how does it work?

Givlaari (givosiran) is an aminolevulinate synthase 1-directed small interfering RNA indicated for the treatment of adults with acute hepatic porphyria (AHP).

What are the side effects of Givlaari?

Advise patients of the potential risks of Givlaari treatment:

Anaphylactic Reaction

  • Inform patients about the risk and possible symptoms of severe hypersensitivity reactions that could occur.

Hepatic Toxicity

  • Inform patients that transaminase elevations may occur, and that laboratory testing will be conducted in the first 6 months of treatment and as clinically indicated thereafter.

Renal Toxicity

  • Inform patients that increases in serum creatinine and decreases in eGFR have been reported and that laboratory testing will be conducted as clinically indicated.

Injection Site Reactions

  • Inform patients of the signs and symptoms of injection site reactions (examples include redness, pain, itching, rash, discoloration, or localized swelling).

Common side effects of Givlaari include:

What is the dosage for Givlaari?

  • The recommended dose of Givlaari is 2.5 mg/kg administered via subcutaneous injection once monthly.
  • Dosing is based on actual body weight.
Missed Dose
  • Administer Givlaari as soon as possible after a missed dose. Resume dosing at monthly intervals following administration of the missed dose.
Dose Modification For Adverse Reactions
  • In patients with severe or clinically significant transaminase
    elevations, who have dose interruption and subsequent improvement, reduce
    the dose to 1.25 mg/kg once monthly.
  • In patients who resume dosing at 1.25 mg/kg once monthly without recurrence of severe or clinically significant transaminase elevations, the dose may be increased to the recommended dose of 2.5 mg/kg once monthly.

What drugs interact with Givlaari?

Sensitive CYP1A2 And CYP2D6 Substrates
  • Concomitant use of Givlaari increases the concentration of CYP1A2 or
    CYP2D6 substrates, which may increase adverse reactions of these substrates.
  • Avoid concomitant use of Givlaari with CYP1A2 or CYP2D6 substrates, for which minimal concentration changes may lead to serious or life-threatening toxicities.
  • If concomitant use is unavoidable, decrease the CYP1A2 or CYP2D6 substrate dosage in accordance with approved product labeling.

Is Givlaari safe to use while pregnant or breastfeeding?

  • There are no available data with Givlaari use in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
  • Consider the benefits and risks of Givlaari for the mother and potential adverse effects to the fetus when prescribing
    Givlaari to a pregnant woman.

  • There are no data on the presence of Givlaari in human milk, the effects on the breastfed child, or the effects on milk production.
  • The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for
    Givlaari and any potential adverse effects on the breastfed child from
    Givlaari or from the underlying maternal condition.

Check Also

강남 셔츠룸 서울부장

강남 셔츠룸 매정한 나라에요 ㅋㅋㅋ 신규오픈 매장으로 설치 물품들이 많습니다. 역시 시부야 아니랄까봐 우리 나라 정서가 두 들겨야 흥이 더 나는듯 합니다. 아직 소버일때 우리 여자 예쁘니 직원들이랑 사진찍고 놀기  5~2배 정도 들었던것같아요 일환이었던 월성 원전 1호기 조기폐쇄에 대한 감사는 수위 조절이 실패해서 포기 햇엇드랫죠;; 대량 매출 가능한 입지라 확신합니다. 게임센터 규모도 장난 아니더라구요 차량…

Leave a Reply